2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116196
    17-HETE 128914-47-6 98.2%
    17-HETE is arachidonic acid metabolite through cytochrome P-450 pathways, which consists of 17R-HETE and 17S-HETE enantiomers. 17-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17-HETE
  • HY-117658
    GSK-114 1301761-96-5 99.52%
    GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue.
    GSK-114
  • HY-119770
    HDL376 147751-31-3 98.62%
    HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.
    HDL376
  • HY-120442
    (±)16(17)-DiHDPA 1345275-27-5 99.0%
    (±)16(17)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)16(17)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis.
    (±)16(17)-DiHDPA
  • HY-121825
    U-44069 56985-32-1 98.0%
    U-44069 is a stable prostaglandin (PG) H2 analogue and a potent vasoconstrictor. U-44069 induces Ca influx at preglomerular vessels.
    U-44069
  • HY-121936
    Yohimbic acid 522-87-2 99.09%
    Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA).
    Yohimbic acid
  • HY-121955
    FW1256 117089-08-4
    FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.
    FW1256
  • HY-122235
    MRL-24 393794-17-7 99.58%
    MRL-24 is a PPARγ agonist. MRL-24 can be used in metabolic disease related research.
    MRL-24
  • HY-122819
    Calindol hydrochloride 729610-18-8 99.88%
    Calindol hydrochloride is a positive allosteric modulator (PAM) of calcimimetic calcium-sensing receptor (CaSR) with an EC50 of 132 nM.
    Calindol hydrochloride
  • HY-122915
    Zedoarondiol 98644-24-7 98.99%
    Zedoarondiol, a sesquiterpene lactone compound, with antioxidant and anti-inflammatory activity. Zedoarondiol can be used for atherosclerosis research.
    Zedoarondiol
  • HY-122917
    Danshenol A 189308-08-5 99.67%
    Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.
    Danshenol A
  • HY-123449
    MK-761 free base 65321-41-7
    MK-761 free base is a potent and orally active β2-adrenergic blocker. MK-761 free base shows antihypertensive and positive inotropic effects. MK-761 free base shows vasodilating properties.
    MK-761 free base
  • HY-124883
    R-(–)-Flecainide 99495-90-6 99.90%
    R-(–)-Flecainide is an orally active antiarrhythmic agent, which inhibits ventricular ectopic activity.
    R-(–)-Flecainide
  • HY-126530
    PPC-NB 1887040-81-4 99.90%
    PPC-NB is a glutathione cleavable linker used for the antibody-drug conjugate (ADC).
    PPC-NB
  • HY-129118
    Takeda103A 865609-72-9 98.69%
    Takeda103A is a potent inhibitor of GRK2. G protein-coupled receptors (GPCRs) are central to many physiological processes. Takeda103A has the potential for the research of heart failure.
    Takeda103A
  • HY-129496
    NP-313 5397-78-4 99.58%
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow.
    NP-313
  • HY-130576
    POVPC 121324-31-0 99.9%
    POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition.
    POVPC
  • HY-131722
    EA4 389614-94-2 98.75%
    EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA2 with a Ki value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis.
    EA4
  • HY-131948
    3-Chlorodiphenylamine 101-17-7 98.74%
    3-Chlorodiphenylamine is a high affinity Ca2+ sensitizer of cardiac muscle. 3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of cardiac troponin C (cTnC) (Kd=6 µM). 3-Chlorodiphenylamine is an excellent starting scaffold for the development of more potent Ca2+-sensitizing compounds due to its small size, and can be used for systolic heart failure research.
    3-Chlorodiphenylamine
  • HY-134769
    OPC-163493 1644467-84-4 99.34%
    OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease.
    OPC-163493
Cat. No. Product Name / Synonyms Application Reactivity